SB-480848 (GlaxoSmithKline)

Research output: Contribution to journalReview articleResearchpeer-review

11 Citations (Scopus)

Abstract

SB-480848 is a reversible lipoprotein-associated phospholipase A 2 inhibitor under development by GlaxoSmithKline for the potential treatment of atherosclerosis. Phase II trials with SB-480848 are currently underway.

Original languageEnglish
Pages (from-to)348-351
Number of pages4
JournalCurrent Opinion in Investigational Drugs
Volume5
Issue number3
StatePublished - 1 Mar 2004

Fingerprint

1-Alkyl-2-acetylglycerophosphocholine Esterase
Atherosclerosis
SB-480848

Cite this

@article{8993d4ce43684290a277e8ba39c22237,
title = "SB-480848 (GlaxoSmithKline)",
abstract = "SB-480848 is a reversible lipoprotein-associated phospholipase A 2 inhibitor under development by GlaxoSmithKline for the potential treatment of atherosclerosis. Phase II trials with SB-480848 are currently underway.",
author = "David Rotella",
year = "2004",
month = "3",
day = "1",
language = "English",
volume = "5",
pages = "348--351",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
publisher = "Current Drugs Ltd.",
number = "3",

}

SB-480848 (GlaxoSmithKline). / Rotella, David.

In: Current Opinion in Investigational Drugs, Vol. 5, No. 3, 01.03.2004, p. 348-351.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - SB-480848 (GlaxoSmithKline)

AU - Rotella, David

PY - 2004/3/1

Y1 - 2004/3/1

N2 - SB-480848 is a reversible lipoprotein-associated phospholipase A 2 inhibitor under development by GlaxoSmithKline for the potential treatment of atherosclerosis. Phase II trials with SB-480848 are currently underway.

AB - SB-480848 is a reversible lipoprotein-associated phospholipase A 2 inhibitor under development by GlaxoSmithKline for the potential treatment of atherosclerosis. Phase II trials with SB-480848 are currently underway.

UR - http://www.scopus.com/inward/record.url?scp=3042668548&partnerID=8YFLogxK

M3 - Review article

VL - 5

SP - 348

EP - 351

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 3

ER -